Tiziana Life Sciences LtdNASDAQ: TLSA

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced it has received non-dilutive funding of $3.4 million which will be used to advance its investigation therapy foralumab. The company highlighted that foralumab is the only fully human anti-CD3 monoclonal antibody (mAb), which binds to the T cell receptor and dampens inflammation by modulating T cell function, therefore suppressing effector features in multiple immune cell subsets.

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough therapies in neurodegenerative disease secondary to active neuroinflammatory processes today announced that it had received non-dilutive funding of $3.4 million and issued a corporate update video available here.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has won approval from the US Food and Drug Administration under an Expanded Access IND to dose its first patient with moderate Alzheimer's disease with its investigational therapeutic intranasal foralumab. Expanded access INDs allow patients to gain access to investigational drugs, biologics and medical devices to treat serious diseases and conditions for which there are no comparable or satisfactory therapy options outside of clinical trials, the biopharmaceutical company said.

NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the U.S. Food and Drug Administration (FDA) has allowed intranasal foralumab to be used under an Expanded Access (EA) IND in its first patient with moderate Alzheimer's disease.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it along with its research partners at Mass General Hospital have been invited to apply for a prestigious grant from the ALS Association to fund a clinical trial evaluating its asset intranasal foralumab. The company said the grant is offered as part of the Hoffman ALS Clinical Trial Awards Program, which helps develop new and improved therapies for ALS by supporting early-stage clinical trials.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the Chairman of its Scientific Advisory Board, Howard L  Weiner, is to receive the “Giants of MS” award. The award ceremony will be held on May 30, 2024, during the Consortium of Multiple Sclerosis Centers annual meeting in Nashville, Tennessee.

NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Howard L. Weiner, M.D., Chairman of Tiziana's Scientific Advisory Board and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital, a founding member of Mass General Brigham healthcare system, is being honored with the prestigious “Giants of MS” award for his outstanding contributions in the area of multiple sclerosis (MS) research. The award ceremony will take place on May 30, 2024 at the Consortium of Multiple Sclerosis Centers annual meeting being held in Nashville, Tennessee.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has asked the FDA to grant orphan drug status to its treatment for multiple sclerosis. If approved, Tiziana's intranasal foralumab would be the first to receive this designation for non-active secondary progressive multiple sclerosis, according to the biotechnology company.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has revealed new neuroimaging results indicating that its experimental drug intranasal foralumab enhanced White Matter Z-scores in patients with non-secondary progressive Multiple Sclerosis (na-SPMS). White Matter Z-scores are a statistical metric in neuroimaging research that evaluates the condition or irregularities of brain structures.